Physician profile
Ujwala Pagedar
NPI 1871627331
$361.38
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $282 · 2020: $55.00 · 2021: $23.98.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $82.94 | 2019-2020 | |
| Alkermes, INC. | $62.95 | 2019-2021 | |
| Amgen INC. | $31.26 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $28.80 | 2019 | |
| Lilly USA, LLC | $27.46 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $24.49 | 2019 | |
| Ethicon US, LLC | $15.12 | 2019 | |
| Ironwood Pharmaceuticals, INC | $14.18 | 2019 | |
| Merck Sharp & Dohme LLC | $13.56 | 2019 | |
| Boston Scientific Corporation | $13.02 | 2019 | |
| Abbvie INC. | $12.66 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.97 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.87 | 2019 | |
| Glaxosmithkline, LLC. | $11.10 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ujwala Pagedar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.